You just read:

New Xultophy® (IDegLira) Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change and Lower Rate of Hypoglycaemia Versus Insulin Glargine

News provided by

Novo Nordisk A/S

07 Jun, 2015, 13:00 BST